G1 Therapeutics

The 'Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024' report by ResearchAndMarkets.com offers comprehensive insights on 10+ companies and 12+ pipeline drugs for mTNBC, including clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products. Key drugs include Trilaciclib by G1 Therapeutics and Olinvacimab by PharmAbcine/Merck, both in advanced clinical stages. The report highlights ongoing R&D efforts, collaborations, and emerging trends in mTNBC treatment.

Jupiter Bioventures, co-founded by Nathaniel David and Norman Sharpless, raises $70 million to establish a biotech foundry focusing on cancer and disease areas. The foundry aims to validate scientific projects ('Moons') before scaling them into independent companies, leveraging a 'science first' model to reduce risk and improve patient outcomes.

Jupiter Bioventures, co-founded by Nathaniel David and Norman Sharpless, raised $70 million to establish a biotech foundry focusing on cancer and disease areas. The financing includes Mission BioCapital, Mayo Clinic, and other investors. Jupiter aims to validate science early to reduce risk and build high-value biotech companies.

Industry-sponsored cancer trials significantly outpace federally sponsored trials in enrollment, prompting concerns over the unique role of federal research in patient-friendly and diverse studies. Federally sponsored trials focus on broader issues like combination therapies and supportive care, unlike industry-sponsored trials primarily aimed at drug approvals. The study highlights the need for increased funding and support for federal trials to ensure comprehensive cancer research.

E. Heath reports advisory/consulting, steering committee, honoraria/paid travel, speaker’s bureau, and research support from various companies. J.R. Ribeiro, K. Poorman, and J. Xiu report personal fees and other support from Caris Life Sciences. H. Mamdani reports other support and grants from Daiichi Sankyo, AstraZeneca, and Genentech. A.F. Shields reports personal fees from Caris Life Sciences. G.L. Lopes reports stock ownership, honoraria, consulting, research funding, travel, and other relationships with multiple companies. S.A. Kareff reports personal fees and travel grants from various organizations. M. Radovich and G.W. Sledge report other support from Caris Life Sciences. G.A. Vidal reports relationships with Guardant360, Gilead, BillionToOne, Genentech/Roche, GSK, and AstraZeneca. J.L. Marshall reports personal fees from Caris. No other disclosures were reported by the other authors.

DelveInsight's 'Breast Cancer Pipeline Insight 2024' highlights a robust pipeline with 100+ companies developing 120+ drugs, driven by rising incidence, tech advancements, and increased awareness. Key companies and drugs include Ambrx, CSPC ZhongQi, Merus, and ARX788, DP303c, SHR-A1811, among others. FDA fast-track designations and breakthrough therapy designations for drugs like 9MW2821 and inavolisib underscore significant progress.